GW Pharmaceuticals, which develops cannabis and other controlled drug-based medicines, reported widening losses and reiterated that research spending is set to rise 30 per cent this year.
Its leading product Sativex, an under-the-tongue spray for the treatment of muscle spasms, stiffness and pain associated with MS, and neuropathic cancer, is on the market in Canada. But a series of setbacks means the regulatory process has taken longer than expected in the UK.
Pre-tax losses widened to £7.1 million from £6 million in the six months to the end of March as research and development expenditure rose by £1.5 million £6.5 million.
Insider's view: dont worry about a 'ting! Email me if you need something to help you relax.
Source: The Times
No comments:
Post a Comment